Inovio Pharmaceuticals Reports 2015 Second Quarter Results; Conference Call Will Discuss New Cancer Partnership
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Inovio Pharmaceuticals (INO) Bullish Stance Reiterated at Stifel
August 10, 2015 11:34 AM EDTStifel analyst Thomas Shrader reiterated a Buy rating and $19 price target on Inovio Pharmaceuticals (NASDAQ: INO) after the company announced Q2 results and a broad partnership with MedImmune to develop INO-3112 in combination with MedImmunes collection of IO molecules.
Shrader said he likes the deal.... More
Inovio Pharmaceuticals (INO) Overweight Rating, $31 PT Reiterated at Piper Jaffray Amid AstraZeneca Deal
August 10, 2015 11:19 AM EDTPiper Jaffray analyst Charles Duncan reiterated his Overweight rating and $31 price target on Inovio Pharmaceuticals (NASDAQ: INO) after the company announced 2Q financials and a partnership with AstraZeneca worth up to $700M ($27.5M upfront + potential development, regulatory, and commercialization milestones) plus tiered double... More
Inovio Pharma (INO) Tops Q2 EPS by 4c
August 10, 2015 6:53 AM EDTInovio Pharma (NASDAQ: INO) reported Q2 EPS of ($0.09), $0.04 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $5.3 million versus the consensus estimate of $5.52 million.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
... More